SCHEMBL4060504

SCHEMBL4060504

COc1ccc(CC(C)CCN)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
ATM Q13315 2/20 0.59
LDHA P00338 1/20 0.53
ALOX15 P16050 2/20 0.53
ALOX12 P18054 2/20 0.53
CA2 P00918 1/20 0.52
STAT3 P40763 1/20 0.47
CYP19A1 P11511 1/20 0.47
FOS P01100 1/20 0.46
TTR P02766 1/20 0.46
JUN P05412 1/20 0.46
NR3C1 P04150 1/20 0.46
HSD17B1 P14061 1/20 0.46
HSD17B2 P37059 1/20 0.46
POLB P06746 3/20 0.45
AOC3 Q16853 1/20 0.45
ALDH1A1 P00352 1/20 0.45
PPARG P37231 1/20 0.45
PPARD Q03181 1/20 0.45
PPARA Q07869 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10558447 0.86 ATM (0.58) KDM4EATMLDHAALOX15ALOX12
SCHEMBL28317357 0.85 SIGMAR1 (0.53) KDM4EALDH1A1SIGMAR1KMT2A
SCHEMBL23966140 0.81 LDHA (0.57) KDM4EATMLDHAALOX15ALOX12
SCHEMBL16973582 0.80 LDHA (0.53) KDM4EATMLDHAALOX15ALOX12
SCHEMBL5494607 0.79 LDHA (0.60) KDM4EATMLDHAALOX15ALOX12
SCHEMBL9026890 0.79 LDHA (0.60) KDM4EATMLDHAALOX15ALOX12
SCHEMBL2564908 0.79 LDHA (0.59) KDM4EATMLDHAALOX15ALOX12
SCHEMBL3371646 0.79 LDHA (0.59) KDM4EATMLDHAALOX15ALOX12
SCHEMBL31545634 0.79 LDHA (0.59) KDM4EATMLDHAALOX15ALOX12
SCHEMBL31545527 0.79 LDHA (0.59) KDM4EATMLDHAALOX15ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569676-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2009-08-04 US disclosed
EP-1498415-B1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS GMBH (DE) 2007-06-27 EP disclosed
US-7060847-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-06-13 US disclosed
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs GHOSHAL MITALI (US) 2005-07-14 US disclosed
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS CORPORATION 2005-01-20 US disclosed
EP-1498415-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs Roche Diagnostics GmbH (DE) 2005-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 KDM4E 1218/4885ATM 4251/4885LDHA 1638/4885
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 KDM4E 1218/4885ATM 4251/4885LDHA 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.